Home » Newsletters » BioWorld

BioWorld

Feb. 5, 1992

View Archived Issues

ORGANOGENESIS TO EXPAND TRIALS

CENTOCOR ACQUIRES DIAGNOSTICS COMPANY

UNIVAX IPO RAKES IN $48 MILLION

ADVANCED POLYMER NETS $8.74 MILLION

ANALYSTS RAISE AMGEN ESTIMATES

ATRIX TO DELAY PERIODONTAL DRUG NDA

LA JOLLA PHARM. RAISES $14 MILLION

U.S. BIO PLANS FEBRUARY MEETING WITH FDA

ANALYSTS QUESTION U.S. BIO STOCK TRADING

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.